SG11202012308TA - Thiophene derivatives for the treatment of disorders caused by ige - Google Patents
Thiophene derivatives for the treatment of disorders caused by igeInfo
- Publication number
- SG11202012308TA SG11202012308TA SG11202012308TA SG11202012308TA SG11202012308TA SG 11202012308T A SG11202012308T A SG 11202012308TA SG 11202012308T A SG11202012308T A SG 11202012308TA SG 11202012308T A SG11202012308T A SG 11202012308TA SG 11202012308T A SG11202012308T A SG 11202012308TA
- Authority
- SG
- Singapore
- Prior art keywords
- ige
- treatment
- disorders caused
- thiophene derivatives
- thiophene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/66—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18179126 | 2018-06-21 | ||
| PCT/EP2019/066414 WO2019243550A1 (en) | 2018-06-21 | 2019-06-20 | Thiophene derivatives for the treatment of disorders caused by ige |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202012308TA true SG11202012308TA (en) | 2021-01-28 |
Family
ID=62748855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202012308TA SG11202012308TA (en) | 2018-06-21 | 2019-06-20 | Thiophene derivatives for the treatment of disorders caused by ige |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20220332709A1 (en) |
| EP (1) | EP3810606A1 (en) |
| JP (1) | JP2021527665A (en) |
| KR (1) | KR20210024571A (en) |
| CN (1) | CN112566910A (en) |
| AR (1) | AR114973A1 (en) |
| AU (1) | AU2019291111B9 (en) |
| BR (1) | BR112020025510A2 (en) |
| CA (1) | CA3103052A1 (en) |
| CL (1) | CL2020003191A1 (en) |
| EA (1) | EA202190011A1 (en) |
| EC (1) | ECSP20080272A (en) |
| IL (1) | IL279482A (en) |
| MA (1) | MA52941A (en) |
| MX (1) | MX2020013882A (en) |
| PE (1) | PE20211803A1 (en) |
| PH (1) | PH12020552162A1 (en) |
| SG (1) | SG11202012308TA (en) |
| TW (1) | TW202016107A (en) |
| UY (1) | UY38271A (en) |
| WO (1) | WO2019243550A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3134221A1 (en) * | 2019-05-10 | 2020-11-19 | Dana-Farber Cancer Institute, Inc. | Small-molecule focal adhesion kinase (fak) inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU616916B2 (en) * | 1987-11-20 | 1991-11-14 | Kissei Pharmaceutical Co. Ltd. | 4h-quinolizin-4-one compounds exhibiting therapeutic activities |
| AU7476800A (en) * | 1999-09-10 | 2001-04-10 | Novo Nordisk A/S | Method of inhibiting protein tyrosine phosphatase 1b and/or t-cell protein tyrosine phosphatase and/or other ptpases with an asp residue at position 48 |
| JP4548882B2 (en) * | 1999-11-30 | 2010-09-22 | 興和創薬株式会社 | 4,5,6,7-tetrahydrothieno [2,3-c] pyridine compound |
| EP1244616A1 (en) * | 1999-12-24 | 2002-10-02 | SmithKline Beecham plc | (hetero)bicyclylmethanesulfonylamino-substituted hydroxamic acid derivatives |
| US6414013B1 (en) * | 2000-06-19 | 2002-07-02 | Pharmacia & Upjohn S.P.A. | Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention |
| WO2005023818A2 (en) * | 2003-09-10 | 2005-03-17 | Gpc Biotech Ag | Heterobicyclic compounds as pharmaceutically active agents |
| US20050085531A1 (en) * | 2003-10-03 | 2005-04-21 | Hodge Carl N. | Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| GB0324653D0 (en) * | 2003-10-22 | 2003-11-26 | Syngenta Participations Ag | Fungicides |
| US8338623B2 (en) * | 2007-07-09 | 2012-12-25 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
| US20110015239A1 (en) * | 2007-12-14 | 2011-01-20 | The Regents Of The University Of California | Inhibitors of calcium-activated chloride channels |
| SG11201600891UA (en) * | 2013-08-08 | 2016-03-30 | Galapagos Nv | Thieno[2,3-c]pyrans as cftr modulators |
-
2019
- 2019-06-20 SG SG11202012308TA patent/SG11202012308TA/en unknown
- 2019-06-20 AU AU2019291111A patent/AU2019291111B9/en active Active
- 2019-06-20 CA CA3103052A patent/CA3103052A1/en active Pending
- 2019-06-20 KR KR1020217002012A patent/KR20210024571A/en active Search and Examination
- 2019-06-20 JP JP2020570719A patent/JP2021527665A/en active Pending
- 2019-06-20 PE PE2020002086A patent/PE20211803A1/en unknown
- 2019-06-20 CN CN201980050341.0A patent/CN112566910A/en active Pending
- 2019-06-20 EA EA202190011A patent/EA202190011A1/en unknown
- 2019-06-20 US US16/973,701 patent/US20220332709A1/en active Pending
- 2019-06-20 BR BR112020025510-6A patent/BR112020025510A2/en unknown
- 2019-06-20 MA MA052941A patent/MA52941A/en unknown
- 2019-06-20 WO PCT/EP2019/066414 patent/WO2019243550A1/en unknown
- 2019-06-20 MX MX2020013882A patent/MX2020013882A/en unknown
- 2019-06-20 EP EP19733448.5A patent/EP3810606A1/en active Pending
- 2019-06-21 UY UY0001038271A patent/UY38271A/en unknown
- 2019-06-21 TW TW108121776A patent/TW202016107A/en unknown
- 2019-06-21 AR ARP190101712A patent/AR114973A1/en unknown
-
2020
- 2020-12-09 CL CL2020003191A patent/CL2020003191A1/en unknown
- 2020-12-11 EC ECSENADI202080272A patent/ECSP20080272A/en unknown
- 2020-12-12 PH PH12020552162A patent/PH12020552162A1/en unknown
- 2020-12-16 IL IL279482A patent/IL279482A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA52941A (en) | 2021-04-28 |
| EA202190011A1 (en) | 2021-04-27 |
| AR114973A1 (en) | 2020-11-11 |
| CL2020003191A1 (en) | 2021-07-02 |
| KR20210024571A (en) | 2021-03-05 |
| TW202016107A (en) | 2020-05-01 |
| AU2019291111A1 (en) | 2021-01-21 |
| CN112566910A (en) | 2021-03-26 |
| WO2019243550A1 (en) | 2019-12-26 |
| UY38271A (en) | 2020-01-31 |
| PE20211803A1 (en) | 2021-09-14 |
| AU2019291111B9 (en) | 2023-08-24 |
| MX2020013882A (en) | 2021-05-27 |
| CA3103052A1 (en) | 2019-12-26 |
| EP3810606A1 (en) | 2021-04-28 |
| BR112020025510A2 (en) | 2021-03-09 |
| IL279482A (en) | 2021-01-31 |
| ECSP20080272A (en) | 2021-01-29 |
| JP2021527665A (en) | 2021-10-14 |
| PH12020552162A1 (en) | 2021-06-28 |
| AU2019291111B2 (en) | 2023-07-06 |
| US20220332709A1 (en) | 2022-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3618829T3 (en) | Quinazoline-pyridine derivatives for the treatment of cancer-related disorders | |
| PL3634417T3 (en) | Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders | |
| HK1219943A1 (en) | Substituted 3-phenylpropylamine derivatives for the treatment of ophthalmic diseases and disorders 3- | |
| IL279260A (en) | Kdm1a inhibitors for the treatment of disease | |
| EP3684418A4 (en) | Methods for the treatment of cysteamine sensitive disorders | |
| HK1256721A1 (en) | Compounds and compositions for the treatment of ocular disorders | |
| IL267818A (en) | Methods for the treatment of neurological disorders | |
| IL272601A (en) | Pharmaceutical compositions for the treatment of ophthalmic conditions | |
| HUE056320T2 (en) | L-valinate amide benzoxaborole derivatives for the treatment of parasitic diseases | |
| ZA202002993B (en) | Compounds for the treatment of neuromuscular disorders | |
| EP3897641C0 (en) | Treatment of movement disorders | |
| IL259674B (en) | Benzofuran derivatives for the treatment of cns and other disorders | |
| HK1216641A1 (en) | 1,2,3-triazole-4-amine derivatives for the treatment of sigma receptor related diseases and disorders 123--4- | |
| EP3593803A4 (en) | Compounds for the treatment of diseases caused by oxalate accumulation | |
| IL279482A (en) | Thiophene derivatives for the treatment of disorders caused by ige | |
| HRP20181391T1 (en) | N-(hetero)aryl-substituted heteroyclic derivatives useful for the treatment of diseases or conditions related to the central nervous system | |
| EP3507277B8 (en) | Hydroxynorketamine derivatives for the treatment of disorders | |
| IT201700057247A1 (en) | KELANIC AGENTS FOR THE TREATMENT OF NUTRITIONAL DISORDERS OF PLANTS | |
| PT3724173T (en) | Compounds for the treatment of neuromuscular disorders | |
| SG11202007642RA (en) | Treatment of disorders with tasimelteon | |
| IT201700006355A1 (en) | COMPOSITION FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | |
| GB201506229D0 (en) | Methods For the Treatment Of Inflammatory Disorders |